Brief: Engene Reports Q2 2024 Financial Results
14/06/2024 12:50
June 14 (Reuters) - enGene Holdings Inc ENGN.O :
* ENGENE REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS AND
PROVIDES A BUSINESS UPDATE
* PLANS FOR INITIAL INDICATION EXPANSION FOR EG-70 INTO
HIGH-RISK
PAPILLARY-ONLY NMIBC
* ENGENE EXPECTS TO FILE A BIOLOGICS LICENSE APPLICATION
(BLA) FOR
EG-70 IN MID-2026
Source text for Eikon: ID:nBwbhdDRHa
Further company coverage: ENGN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on enGene Therapeutics
See all newsBrief: Engene Reports Second Quarter 2026 Financial Results And Provides Business Update
enGene Therapeutics Inc expected to post a loss of 47 cents a share - Earnings Preview
Brief: Engene Holdings Inc - To Change Name To Engene Therapeutics Inc. Effective April 8, 2026
Brief: Engene Holdings Enters Sales Agreement With Leerink Partners To Sell Common Shares
Brief: enGene Reports First Quarter 2026 Financial Results and Provides Business Update